Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Impact of Incubators on Venture Investing

This article was originally published in Start Up

Executive Summary

It seems logical that an incubator should facilitate venture fund investment in early-stage biomedical companies, since the incubator should accelerate technology commercialization. Unfortunately, few incubators--at least on the biotech side--have realized this potential, for a variety of reasons.

You may also be interested in...



Innovating on Biotech Investment Models: Likely--or Even Possible?

With the lack of a public market, VCs have grown extremely chary of new investments: are there lessons to be learned for biotech investing from the models employed by device investors or other apparently lower-risk approaches, such as "defined liquidity ventures"?

The Comparative Advantages of Medical Device Investing

Given the currently dismal valuations of public biotechnology companies and with no near-term expectation of an upturn in investor appetites, venture funds are increasingly interested in medical device investing thanks to their lower capital costs and likely exits via acquisitions. Answer: Yes. A hostile public market environment reminds one of the many advantages of investing in medical device companies.

The Comparative Advantages of Medical Device Investing

Given the currently dismal valuations of public biotechnology companies and with no near-term expectation of an upturn in investor appetites, venture funds are increasingly interested in medical device investing thanks to their lower capital costs and likely exits via acquisitions. Answer: Yes. A hostile public market environment reminds one of the many advantages of investing in medical device companies.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090354

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel